Aberrant activation of β-
catenin has been implicated in a variety of human diseases, including
cancer. In spite of significant progress, the regulation of active Wnt/β-
catenin-signaling pathways is still poorly understood. In this study, we show that
F-box protein 16 (FBXO16) is a putative
tumor suppressor. It is a component of the SCF (SKP1-Cullin1-F-box protein) complex, which targets the nuclear β-
catenin protein to facilitate proteasomal degradation through the
26S proteasome. FBXO16 interacts physically with the C-terminal domain of β-
catenin and promotes its
lysine 48-linked polyubiquitination. In addition, it inhibits epithelial-to-mesenchymal transition (EMT) by attenuating the level of β-
catenin. Therefore, depletion of FBXO16 leads to increased levels of β-
catenin, which then promotes cell invasion,
tumor growth, and EMT of
cancer cells. Furthermore, FBXO16 and β-
catenin share an inverse correlation of cellular expression in clinical
breast cancer patient samples. In summary, we propose that FBXO16 functions as a putative
tumor suppressor by forming an SCFFBXO16 complex that targets nuclear β-
catenin in a unique manner for ubiquitination and subsequent proteasomal degradation to prevent
malignancy. This work suggests a novel therapeutic strategy against human
cancers related to aberrant β-
catenin activation. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.